Eli Lilly LLY Additional Paid-In Capital
Additional Paid-In Capital at other companies
Other financials
Where this comes from
Reported directly by Eli Lilly in its filing.
Tagged under the XBRL concept us-gaap:AdditionalPaidInCapitalCommonStock.
The official record: Eli Lilly’s 10-Q, filed April 30, 2026, on SEC EDGAR. View the filing →
Ask your AI about Eli Lilly's additional paid-in capital.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Eli Lilly's additional paid-in capital?
- Eli Lilly (LLY) reported additional paid-in capital of $6.92B in Q1 2026.
- How has Eli Lilly's additional paid-in capital changed year-over-year?
- Eli Lilly's additional paid-in capital increased by 0.2% year-over-year, from $6.91B to $6.92B.
- What is the long-term trend for Eli Lilly's additional paid-in capital?
- Over 5 years (2020 to 2025), Eli Lilly's additional paid-in capital has grown at a 1.6% compound annual growth rate (CAGR), from $6.78B to $7.35B.
- What does additional paid-in capital mean?
- This represents the excess amount paid by investors for common shares over their par value. It is a key component of shareholders' equity that captures the capital raised through equity offerings beyond the nominal value of the stock. It reflects the historical market premium at which the company has issued its shares.